Identification of CDCP1 as a hypoxia-inducible factor 2α (HIF-2α) target gene that is associated with survival in clear cell renal cell carcinoma patients
about
Preconditioning of mesenchymal stem cells by sevoflurane to improve their therapeutic potentialNovel small molecule inhibiting CDCP1-PKCδ pathway reduces tumor metastasis and proliferation.Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer.Cell-Surface Protein Profiling Identifies Distinctive Markers of Progenitor Cells in Human Skeletal MuscleCDCP1 cleavage is necessary for homodimerization-induced migration of triple-negative breast cancer.Hypoxia promotes the phenotypic change of aldehyde dehydrogenase activity of breast cancer stem cells.The signaling pathway of hypoxia inducible factor and its role in renal diseases.New crossroads for potential therapeutic intervention in cancer - intersections between CDCP1, EGFR family members and downstream signaling pathways.Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance.EGF inhibits constitutive internalization and palmitoylation-dependent degradation of membrane-spanning procancer CDCP1 promoting its availability on the cell surface.HIF-2α regulates CDCP1 to promote PKCδ-mediated migration in hepatocellular carcinoma.miR-198 functions as a tumor suppressor in breast cancer by targeting CUB domain-containing protein 1.CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers.Bagging Nearest-Neighbor Prediction independence Test: an efficient method for nonlinear dependence of two continuous variables.CDCP1 drives triple-negative breast cancer metastasis through reduction of lipid-droplet abundance and stimulation of fatty acid oxidation.Cub domain containing protein 1 (CDCP1) negatively regulates TGFβ signaling and myofibroblast differentiation.Hypoxia-Inducible Factor 2-Dependent Pathways Driving Von Hippel-Lindau-Deficient Renal Cancer.
P2860
Q31153106-9647E296-EBE0-448E-BF80-215736AF5C82Q33738983-051E4205-D24D-4EC4-890C-94C08A37D21EQ36750564-217ED73E-A2AC-41DA-A00F-D71E42195091Q37171530-4EBEC018-F8CE-4070-A22C-6A8FB4380A68Q37176588-363ACAC6-C131-4C09-A456-5B394561E87DQ37735635-1357EDA2-C710-4245-9AE9-00BA819C07A2Q38131006-52112022-DF85-4C1C-886C-C30E6E729C0CQ38388622-4ADCFC70-A85C-41C2-B6B8-C15D6A261060Q38884686-84C326F4-8BC8-4E0F-B664-BC14723BA2C8Q39010253-AC69268C-657D-4F7E-ACDE-4288B18ADCB4Q40607212-1542E1B5-F393-4E46-8211-4CBED9CB5D95Q42290612-7D2F6276-B4E1-4343-A1E2-85AA1496E983Q42317491-51882210-C548-4C2C-B677-C323E6E8FCE6Q42371830-D7EBD221-6553-45FF-8E58-9C74FA5C6434Q46085514-E68A84E8-AB98-4D54-8296-1BC209D1F67EQ47652548-49ADC93A-EEFD-496F-A10F-D10F156F6CFCQ55419613-1EB131D3-D981-4D39-9FFB-02B6F6C241B9
P2860
Identification of CDCP1 as a hypoxia-inducible factor 2α (HIF-2α) target gene that is associated with survival in clear cell renal cell carcinoma patients
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Identification of CDCP1 as a h ...... renal cell carcinoma patients
@ast
Identification of CDCP1 as a h ...... renal cell carcinoma patients
@en
type
label
Identification of CDCP1 as a h ...... renal cell carcinoma patients
@ast
Identification of CDCP1 as a h ...... renal cell carcinoma patients
@en
prefLabel
Identification of CDCP1 as a h ...... renal cell carcinoma patients
@ast
Identification of CDCP1 as a h ...... renal cell carcinoma patients
@en
P2093
P2860
P356
P1476
Identification of CDCP1 as a h ...... renal cell carcinoma patients
@en
P2093
Brooke M Emerling
Cyril H Benes
Eric L Bell
Gary Bellinger
Kazumi S Tsukazawa
Kevin Courtney
Rayman Choo-Wing
Sabina Signoretti
Stephen P Soltoff
P2860
P304
P356
10.1073/PNAS.1222435110
P407
P577
2013-02-01T00:00:00Z